Last reviewed · How we verify
NCT02575560
Weekly Use First-generation EGFR-TKI in the Treatment of EGFR-TKI Acquired Resistance Non-small Cell Lung Cancer (NSCLC)
trial testing history data in EGFR-TKI Resistant Mutation in 30 participants. Completed in 31 December 2017.
30 September 2017
Quick facts
| Lead sponsor | Qingdao Central Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 1 October 2015 |
| Primary completion | 30 September 2017 |
| Estimated completion | 31 December 2017 |
| Sites | 1 location across China |
Drugs / interventions tested
- history data
Conditions studied
- EGFR-TKI Resistant Mutation — all drugs for EGFR-TKI Resistant Mutation →
Sponsor
Qingdao Central Hospital
Who can join
Adults 18 to 80, any sex, with EGFR-TKI Resistant Mutation. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
EGFR-TKI is the main is the first line therapy for local advanced or metastatic non-small cell lung cancer with EGFR gene mutation. The median progression free survival time is around 11 months with the first generation EGFR-TKI. Patients with acquired resistance with first generation EGFR-TKI usually with EGFR exon 20 mutation (T790M). Change the drug administration maybe prolong patients PFS and evently prolong OS.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT02575560
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for EGFR-TKI Resistant Mutation
Currently open trials in the same condition.
- NCT06363734 — Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT06071013 — Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients · Phase 1, PHASE2 · recruiting
- NCT05598528 — Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Adv · recruiting
Other Qingdao Central Hospital trials
Trials by the same sponsor.
- NCT07090525 — Bevacizumab Combined With Cisplatin Versus Cisplatin Monotherapy in Malignant Serous Effusions · Phase 2 · recruiting
- NCT07090031 — Perioperative Treatment With TAS-102 in Combination With Oxaliplatin for Locally Advanced Rectal Cancer · Phase 2 · active not recruiting
- NCT07322783 — Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification · Phase 2 · recruiting
- NCT06500234 — Nutrition Impact on Immunotherapy of Cancer · Phase 3 · recruiting
- NCT06514118 — Chemoimmunotherapy Plus Residual Lesion Irradiation for the Treatment of Extensive Stage Small-cell Lung Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02575560 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Qingdao Central Hospital
- Last refreshed: 14 February 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02575560.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing